The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
暂无分享,去创建一个
Daniel J Sargent | Greg Yothers | Qian Shi | Winson Y Cheung | Michael O'Connell | D. Kerr | D. Sargent | E. Van Cutsem | M. O’connell | S. Alberts | G. Yothers | J. Cassidy | W. Cheung | Q. Shi | Eric Van Cutsem | David J Kerr | James Cassidy | C. Blanke | Charles D Blanke | Steven R Alberts | Jeff Meyers | J. Meyers
[1] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[2] F. Morrone,et al. Gender differences, polypharmacy, and potential pharmacological interactions in the elderly , 2011, Clinics.
[3] N. Petrelli,et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] F. D. De Braud,et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Kerr,et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Booton,et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] A. Bezjak,et al. The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] A. Jemal,et al. Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates , 2010, Cancer.
[9] K. Armstrong,et al. Gender Influences Treatment and Survival in Colorectal Cancer Surgery , 2009, Diseases of the colon and rectum.
[10] H. Lenz,et al. Gender Disparities in Metastatic Colorectal Cancer Survival , 2009, Clinical Cancer Research.
[11] T. Hickish,et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Kneebone,et al. Improved Survival in Young Women With Colorectal Cancer , 2008, The American Journal of Gastroenterology.
[13] L. Påhlman,et al. The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region. , 2007, Critical reviews in oncology/hematology.
[14] N. Petrelli,et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Colditz,et al. Hormone replacement therapy and survival after colorectal cancer diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Nancy Breen,et al. Patterns of Colorectal Cancer Screening Uptake among Men and Women in the United States , 2006, Cancer Epidemiology Biomarkers & Prevention.
[17] J. Wardle,et al. Gender differences in utilization of colorectal cancer screening , 2005, Journal of medical screening.
[18] F. Shepherd,et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. , 2005, Journal of Clinical Oncology.
[19] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[20] C. McArdle,et al. Male gender adversely affects survival following surgery for colorectal cancer , 2003, The British journal of surgery.
[21] S. Cha,et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Wichmann,et al. Gender differences in long‐term survival of patients with colorectal cancer , 2001, The British journal of surgery.
[23] P J Catalano,et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.
[24] J. Sloan,et al. Sex differences in fluorouracil-induced stomatitis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] X. Pivot,et al. Cisplatin Nephrotoxicity: A Multivariate Analysis of Potential Predisposing Factors , 1997, Pharmacotherapy.
[26] S. Barni,et al. Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients , 1997, Supportive Care in Cancer.
[27] F. Demard,et al. Influence of sex and age on fluorouracil clearance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.